Trials / Completed
CompletedNCT03817463
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Multi-country Non-interventional Study on the Effectiveness of Empagliflozin in Adult Patients With Type 2 Diabetes in Europe and Asia.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 327,624 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor | Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor |
| DRUG | Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor | Dipeptidyl peptidase-4 (DPP-4) inhibitor |
Timeline
- Start date
- 2019-04-15
- Primary completion
- 2021-12-10
- Completion
- 2021-12-10
- First posted
- 2019-01-25
- Last updated
- 2024-09-23
- Results posted
- 2024-09-23
Locations
13 sites across 11 countries: Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03817463. Inclusion in this directory is not an endorsement.